Breast Cancer News | Merck's Keytruda was approved in Europe for certain patients with TNBC

Spinal Muscular Atrophy News

NICE ASSESSMENT OUTCOMES

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

ASCO 2021

NHS England News | NHS to offer Tagrisso for lung cancer patients

United Kingdom COVID19 News | Has Britain reached herd immunity?

CMS News | US Healthcare News | Medicare and Medicaid News |

European Commission approved Benlysta for active lupus nephritis

France COVID-19 Updates | COVID-19 News in Europe

Top pharmaceutical companies by revenues in 2021

COVID-19 India Updates

American Academy of Dermatology (AAD VMX) Virtual Meeting

Top 20 pharmaceutical companies by revenues in 2020

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

Multiple sclerosis News | Tysabri is now available as SC in Europe

Gilead’s Trodelvy approved for triple-negative breast cancer in US

England patients to benefit from Phesgo, 5-minute breast cancer treatment from Roche

CHMP Opinions | EMA drug approvals

Is AstraZeneca and Oxford’s COVID vaccine safe? Australia prefers Pfizer vaccine

BMS’ and bluebird bio’s Abecma approved by US FDA; first CAR T cell therapy for multiple myeloma

HAS ASSESSMENT OUTCOMES | FRANCE PHARMA NEWS

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

Levima received orphan designation from MHLW |Japan drug approvals | Japan Healthcare System

TGA Approved Zolgensma | TGA Drug approvals

FDA drug approvals| Actemra approved for SSc-ILD | Libtayo for NSCLC

Novartis’ blockbuster Entresto received the US FDA approval for a broader target population

US FDA approved BMS gene therapy Breyanzi

2021 Access to Medicine Index: GSK tops the list, followed Novartis and J&J

Merck and Bayer announced the US FDA approval for Verquvo

Expected best selling pharmaceutical products (drugs) in 2021

What Sanofi is expecting to achieve with the acquisition of Kymab?

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients

Lynparza was approved for three more indications in Japan

Kite’s CAR-Tcell therapy received approval in Europe for relapsed or refractory mantle cell lymphoma

ViiV healthcare’s Vocabria received approval in Europe for HIV infection

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

CMS News

European Commission to purchase 200 million doses of Johnson and Johnson's COVID 19 vaccine